Single dose administration of factor VIIa
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
1. A method for treating a bleeding episode in a human subject in need of such treatment, said method comprising administering intravenously to said human subject purified Factor VIIa wherein said administering is in a single dose and said dose comprises a single-dose-effective amount of said Factor VIIa, wherein said single-dose-effective amount comprises between 200 and 500 μg/kg Factor VIIa and wherein, subsequent to said administration, no further Factor VIIa is administered to said subject for a period of at least 4 hours.
2. A method as defined in claim 1 , wherein said period is at least 24 hours.
3. A method as defined in claim 1 , wherein said single dose is administered over a period of less than 5 minutes.
4. A method as defined in claim 1 , further comprising administering, in said single dose, or substantially simultaneously with said single dose, a second coagulant agent.
5. A method as defined in claim 4 , wherein said second coagulant agent is selected from the group consisting of Factor VIII, Factor IX, and Factor XIII.
6. A method as defined in claim 1 , further comprising administering an anticoagulant, wherein said anticoagulant is administered in said single dose, or substantially simultaneously with said single dose.
7. A method for treating a bleeding episode, said method comprising administering intravenously to a human subject in need of such treatment (i) a first amount of purified Factor VIIa and (ii) a second amount of second coagulant agent, wherein said first amount consists of between 200 and 500 μg/kg Factor VIIa and wherein said first and second amounts together comprise an aggregate effective amount for treating said bleeding and said aggregate effective amount is administered in a single dose, and wherein, subsequent to said administration, no further Factor VIIa is administered to said subject for a period of at least 4 hours.
8. A method for treating a bleeding episode, said method comprising administering intravenously to a human subject in need of such treatment an effective amount for treating said bleeding of purified human Factor VIIa, wherein:
(i) said effective amount is administered in a single dose over a period of less than 5 minutes;
(ii) said effective amount comprises between 200 and 500 μg/kg human Factor VIIa; and
(iii) subsequent to said administration, no further Factor VIIa is administered to said subject for a period of at least 4 hours,
wherein said human subject suffers from a bleeding disorder.